Stock events for Thermo Fisher Scientific, Inc. (TMO)
Over the past six months, Thermo Fisher Scientific's stock (TMO) has experienced several notable events impacting its price. Between September 27, 2024, and September 26, 2025, the share price declined. On October 1, 2025, the stock surged due to market optimism surrounding strategic developments, including the acquisition of Solventum's purification and filtration business, the completion of the acquisition of Sanofi's sterile fill-finish and packaging site, and a substantial investment in its U.S. operations. On October 3, 2025, TMO shares jumped following the launch of a new high-performance product and a positive analyst rating from Barclays. Two days prior to October 3, 2025, the stock gained on news of a major manufacturing agreement with biotechnology firm Vaxcyte and a new AI-focused partnership. On October 2, 2025, Barclays maintained its "Overweight" rating and raised its price target for TMO.
Demand Seasonality affecting Thermo Fisher Scientific, Inc.’s stock price
Demand for Thermo Fisher Scientific's products and services generally exhibits a resilient nature, particularly in the life sciences and diagnostics sectors. A "seasonal uptick in trial starts" could act as a catalyst for increased demand. The company experienced a significant surge in sales during 2020 and 2021 due to the COVID-19 pandemic. The subsequent "end of the pandemic bump" has been noted as a potential short to medium-term risk, suggesting that demand in certain areas that were heavily influenced by the pandemic may normalize or decrease.
Overview of Thermo Fisher Scientific, Inc.’s business
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing a comprehensive range of products and services across various scientific and healthcare sectors, operating primarily in the life science and clinical research sectors. The company's core business revolves around providing innovative solutions to customers in life sciences, healthcare, and industrial markets. Its major products and services are categorized into four segments: Life Sciences Solutions offers reagents, instruments, and consumables for biological and medical research, drug and vaccine discovery and production, and diagnosis of infections and diseases. Analytical Instruments provides advanced instruments, consumables, software, and services for material analysis, environmental testing, industrial applications, and clinical laboratories. Specialty Diagnostics supports clinical laboratories and healthcare providers with diagnostic tools and services. Laboratory Products and Biopharma Services offers essential laboratory equipment, consumables, and biopharma services. The company markets its products through a direct sales force, customer service professionals, e-commerce, and third-party distributors under various brands.
TMO’s Geographic footprint
Thermo Fisher Scientific has a significant global presence, serving customers worldwide, including North America, Europe, and Asia-Pacific. In fiscal year 2024, the United States accounted for the largest share of its revenue at $22.50 billion, followed by Europe ($10.86 billion), Asia Pacific ($7.96 billion), and All Other Countries ($1.56 billion). The company has also recently expanded its central laboratory operations in Kentucky, adding a new 65,000-square-foot space in Covington to enhance sample management and biorepository operations, complementing its existing site in Highland Heights.
TMO Corporate Image Assessment
In the past year, Thermo Fisher Scientific has maintained a strong brand reputation, largely driven by its strategic growth initiatives, continuous innovation, and critical role in scientific advancement. Positive analyst ratings reflect confidence in the company's future performance and market positioning. Recent strategic acquisitions have been met with market optimism, indicating a positive perception of the company's expansion into high-growth sectors and its ability to meet increasing demand in pharmaceutical and biotech manufacturing. The launch of new products further solidifies its reputation as a leader in providing advanced research tools. Additionally, partnerships contribute positively to its global standing and commitment to scientific development.
Ownership
Thermo Fisher Scientific's stock is predominantly owned by institutional investors, who hold approximately 88.50% to 89.77% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Insider ownership is relatively low, ranging from 0.11% to 0.89%. Retail investors hold between 10.62% and 30.89% of the stock.
Ask Our Expert AI Analyst
Price Chart
$525.83